This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study of ABT-751 in Patients With Colorectal Cancer

This study has been completed.
Information provided by:
Abbott Identifier:
First received: November 17, 2003
Last updated: November 28, 2007
Last verified: November 2007
The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with colorectal cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.

Condition Intervention Phase
Colorectal Cancer Drug: ABT-751 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of ABT-751 in Subjects With Refractory Colorectal Carcinoma

Resource links provided by NLM:

Further study details as provided by Abbott:

Primary Outcome Measures:
  • Objective Response Rate in subjects with Recurrent Colorectal Cancer [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Time to Tumor Progression (TTP) [ Time Frame: 1 year ]
  • Survival [ Time Frame: 2 years ]
  • Toxicities associated with treatment administration [ Time Frame: 1 year ]

Estimated Enrollment: 40
Study Start Date: August 2003
Study Completion Date: February 2005

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Colorectal cancer.
  • Recurrent tumor following treatment with irinotecan and/or oxaliplatin.
  • Able to tolerate normal activities of daily living.
  • Adequate bone marrow, kidney, and liver function.

Exclusion Criteria

  • Pregnant or breast feeding.
  • Anti-tumor therapy within 4 weeks of the start of ABT-751 administration.
  • Prior radiation therapy.
  • CNS metastasis.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00073138

United States, California
University of Southern California
Los Angeles, California, United States, 90089
Cancer Institute Medical Group
Santa Monica, California, United States, 90095-3961
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611-5933
University of Chicago Medical Center
Chicago, Illinois, United States, 60637
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, Wisconsin
University of Wisconsin Medical Center
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
Study Director: Helen Eliopoulos, MD Abbott
  More Information Identifier: NCT00073138     History of Changes
Other Study ID Numbers: M02-446
Study First Received: November 17, 2003
Last Updated: November 28, 2007

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases processed this record on September 21, 2017